Home > Healthcare > Medical Devices > Diagnostic Devices > Point of Care Infectious Disease Testing Market

Point of Care Infectious Disease Testing Market Share

Report ID: GMI11938
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Point of Care Infectious Disease Testing Market Share

The market is characterized by a competitive landscape with major global companies and smaller to medium-sized firms vying for market share. A central strategy involves the continuous development of innovative testing solutions that enhance diagnostic accuracy and speed. Key industry players drive advancements through substantial investments in research and development to improve testing methodologies and patient accessibility.

Strategic alliances, partnerships, and collaborations are essential for strengthening market positions and expanding global reach in response to evolving regulatory standards and increasing demand for rapid POC testing solutions, particularly as the emphasis on decentralized healthcare and the integration of telehealth services grows.

Point of Care Infectious Disease Testing Market Companies

Some of the eminent market participants operating in the point of care infectious disease testing industry include:

Abbott Laboratories
Becton, Dickinson and Company
Biomerieux
Bio-Rad Laboratories
Cardinal Health
Chembio Diagnostics
Danaher Corporation
F. Hoffmann-La Roche
OJ-Bio
QuidelOrtho Corporation
Siemens Healthineers
Trinity Biotech
Trivitron Healthcare

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global point-of-care infectious disease testing industry was valued at approximately USD 3.2 billion in 2023 and is estimated to grow at a 6.9% CAGR from 2024 to 2032, driven by the need for rapid diagnostic results.

The kits and reagents segment generated USD 2.5 billion in revenue in 2023 and is expected to grow significantly due to their ease of use and quick turnaround times, which are crucial in various healthcare settings.

North America's market accounted for a 46.6% revenue share in 2023 and is projected to reach USD 2.7 billion by 2032, supported by a robust healthcare system and advanced technology.

Key players in the market include Abbott Laboratories, Becton, Dickinson and Company, Biomerieux, Bio-Rad Laboratories, Cardinal Health, Chembio Diagnostics, Danaher Corporation, F. Hoffmann-La Roche, OJ-Bio, and QuidelOrtho Corporation.